BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37219067)

  • 1. Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia.
    Namikawa H; Imoto W; Yamada K; Tochino Y; Kaneko Y; Kakeya H; Shuto T
    Emerg Microbes Infect; 2023 Dec; 12(1):2217951. PubMed ID: 37219067
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis.
    Jiang AM; Liu N; Zhao R; Zheng HR; Chen X; Fan CX; Zhang R; Zheng XQ; Fu X; Yao Y; Tian T
    Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):53. PubMed ID: 33228668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
    Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
    Lim CL; Spelman D
    Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
    Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
    J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
    Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
    Zhang H; Liang B; Wang J; Cai Y
    Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam.
    Namikawa H; Yamada K; Yamairi K; Shibata W; Fujimoto H; Takizawa E; Niki M; Nakaie K; Oinuma KI; Niki M; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):287-292. PubMed ID: 31005401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
    Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
    Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
    Schwaber MJ; Carmeli Y
    J Antimicrob Chemother; 2007 Nov; 60(5):913-20. PubMed ID: 17848376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
    Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
    Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Palacios-Baena ZR; Gutiérrez-Gutiérrez B; De Cueto M; Viale P; Venditti M; Hernández-Torres A; Oliver A; Martínez-Martínez L; Calbo E; Pintado V; Gasch O; Almirante B; Antonio Lepe J; Pitout J; Akova M; Peña-Miralles C; Schwaber MJ; Tumbarello M; Tacconelli E; Origüen J; Prim N; Bou G; Giamarellou H; Bermejo J; Hamprecht A; Pérez F; Almela M; Lowman W; Hsueh PR; Navarro-San Francisco C; Torre-Cisneros J; Carmeli Y; Bonomo RA; Paterson DL; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 Mar; 72(3):906-913. PubMed ID: 28062685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
    Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology, risk factors and treatment outcomes of extended-spectrum beta-lactamase producing Enterobacteriaceae bacteremia among children in a Tertiary Care Hospital, Bangkok, Thailand.
    Nivesvivat T; Piyaraj P; Thunyaharn S; Watanaveeradej V; Suwanpakdee D
    BMC Res Notes; 2018 Aug; 11(1):624. PubMed ID: 30157960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia.
    Kim SJ; Park KH; Chung JW; Sung H; Choi SH; Choi SH
    Korean J Intern Med; 2014 Sep; 29(5):637-46. PubMed ID: 25228840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.